Australia Biotechnology and Genomics Market Size, Share, Growth and Forecast, 2025-2035

Medicare and sovereign plants reshape Australian biotech

The Australia biotechnology and genomics market was valued at USD 7.94 billion in 2025 and is projected to increase from USD 8.60 billion in 2026 to USD 17.14 billion by 2035, registering a CAGR of 7.96% during 2026–2035. Demand comes from subsidized biologic medicines, Medicare-funded genomic tests, early-phase clinical trials, sovereign vaccine contracts and licensed crop traits. Victoria and New South Wales held the largest regional share, 53.9% in 2025, supported by vaccine plants in Melbourne and a new RNA facility in Sydney. Queensland is the fastest-growing region at 8.51% a year, helped by translational science investment and planned fermentation capacity in Mackay. Commercial conditions are changing as well, because Genomics Australia began work on July 1, 2025, while the 2026–27 federal budget proposes narrower access to refundable research tax offsets from July 1, 2028.

What does the Australian biotechnology and genomics market count, and who pays?

The market counts human health biologics and cell therapies, agricultural and industrial biotechnology products, and genomics services sold to Australian buyers. Payment comes mainly through the Pharmaceutical Benefits Scheme, Medicare rebates, state health procurement, private pathology, sponsors of clinical trials and research institutes.

The estimate excludes medical devices without a biological or genomic function, general chemistry pathology and small-molecule generics. The value chain runs from university discovery and contract research through regulated manufacturing to reimbursed clinical supply, with licensing income supporting companies whose lead products are still in trials.

Human health and public buyers set the demand base

Why human health biotechnology leads the product mix

Based on product type, the market is categorized into human health biotechnology, agricultural biotechnology, industrial biotechnology and genomics services. Human Health Biotechnology led with 62.0% of 2025 value because subsidized biologic medicines anchor spending, and the Australian Institute of Health and Welfare counted six biologics among the 10 costliest Pharmaceutical Benefits Scheme medicines in 2022–23. Genomics Services grows fastest at 9.42% a year as Medicare demand widens, after the Department of Health recorded more than 376,000 subsidized genetic and genomic tests in 2022–23. Crop and fermentation work remains smaller, although both hold licensed or planned commercial assets in Queensland.

Public purchasers fund the largest share of demand

Based on customer type, the market is categorized into public health purchasers, private healthcare providers, biopharmaceutical companies and research and bioeconomy customers. Public Health Purchasers led with 44.0% because federal reimbursement sets the largest budgets, and the Australian Institute of Health and Welfare reported that government paid A$17.0 billion, or 83%, of the A$20.4 billion spent on subsidized medicines in 2022–23. Research and Bioeconomy Customers grows fastest at 9.31% a year as research funding scales, with Opportuna Legal's review of the 2026–27 federal budget showing Medical Research Future Fund disbursements rising from A$650 million in 2025–26 to A$1 billion from 2030–31.

Diagnosis and treatment outweigh research applications

Based on application, the market is categorized into disease diagnosis and treatment, drug discovery and clinical development, crop and animal improvement, and bioprocess and material optimization. Disease Diagnosis and Treatment led with 58.0% because cancer and immune care absorb the highest-cost therapies, and the Australian Institute of Health and Welfare attributed about 39% of 2022–23 government medicine spending to antineoplastic and immunomodulating agents. Bioprocess and Material Optimization grows fastest at 9.68% a year as fermentation moves toward commercial scale, including a Cauldron plant planned for Mackay at more than 1,000 metric tons a year, according to a September 2024 company release. Demand for drug discovery laboratory services follows trial activity at sponsors nationwide.

Cell-based plants lead while sequencing grows fastest

Based on technology, the market is categorized into cell-based biomanufacturing, molecular assay platforms, genomic sequencing and computational biology. Cell-Based Biomanufacturing led with 46.0% because large dedicated plants define national supply, and CSL Seqirus opened its A$1 billion Tullamarine cell-based vaccine facility in late 2025, according to Australian Manufacturing. Genomic Sequencing grows fastest at 9.26% a year as cancer profiling gains federal backing, with the 2026–27 budget allocating A$71.0 million over three years to the PrOSPeCT genomic profiling program, according to Opportuna Legal. Sequencing access also broadens through the South Australian Genomics Centre's Flinders node, an investment above A$7 million.

Rebates, research funds and plants lift spending

Clinical genomics translation through Medicare rebates

Clinical genomics is moving from research into reimbursed practice, which lifts recurring test volumes for laboratories and cancer centers. The federal government committed A$148.5 million over four years for 34 new, expanded or increased Medicare rebates from Nov. 1, 2023, serving about 112,000 people a year. That package followed more than 376,000 subsidized tests and about A$76.8 million in benefits during 2022–23. Genomics Australia then began work on July 1, 2025, with over A$30 million for its first four years, according to the Department of Health. As a result, genetic testing providers can plan around the updated National Health Genomics Policy Framework, while reproductive carrier screening alone is expected to reach about 85,000 people each year.

Research incentives and commercial runway for developers

Public research money and tax offsets let young companies fund longer clinical programs before product income arrives. Opportuna Legal's review of the 2026–27 federal budget records A$508.5 million over four years in added Medical Research Future Fund disbursements, plus A$15.8 million over two years for a national clinical trial approval platform. AusBiotech counted more than 350,000 supported jobs across almost 3,000 organizations in June 2026, up from 2,654 organizations in its 2022 snapshot reported by BiotechDispatch. That runway can produce exportable assets, as shown when the FDA approved Ryoncil from Mesoblast on Dec. 18, 2024, for children aged two months and older with steroid-refractory acute graft-versus-host disease.

Download Free Sample

Sequencing productivity and wider service breadth

Wider instrument choice and shared facilities let smaller sponsors order whole-genome, single-cell and spatial studies without buying their own platforms. The Australian National University's John Curtin School of Medical Research lists Illumina, PacBio Revio and Oxford Nanopore PromethION sequencing among its services. The Flinders University node of the South Australian Genomics Centre, established in July 2020 with more than A$7 million invested, adds Stereo-seq and Xenium spatial systems and handles up to 1 million cells per Evercode experiment. Budget planning also remains open, since a March 2026 Value in Health study reported observed testing volumes below diffusion-implied trajectories and suggested likely under-budgeting. Consequently, Genomic Sequencing holds the fastest technology growth at 9.26% a year across the forecast period.

Sovereign supply contracts anchor domestic plants

Long-term government supply agreements underwrite plants that private demand alone would struggle to justify. Moderna opened its Clayton facility on Dec. 4, 2024, with capacity for up to 100 million doses a year under a 10-year partnership with the federal and Victorian governments, according to Investment Monitor. CSL Seqirus backs its Tullamarine site with a 12-year federal agreement running through 2036, according to Australian Manufacturing. In New South Wales, an A$96 million RNA facility covering 4,500 square meters opened at Macquarie University in April 2026, according to LabOnline. These commitments feed local contract manufacturing work and help the southern states keep their lead in national supply.

RNA capacity and crop licenses open new revenue pools

RNA capacity shifts beyond a single Victorian plant

RNA production is spreading across states, which gives developers more domestic options for early and pilot batches. The Macquarie University facility, operated with industry partner Aurora Biosynthetics, is described by the New South Wales government as the only Australian site able to produce a wide range of RNA therapeutics under one roof, according to LabOnline. In July 2024, Western Australia's Future Health Research and Innovation Fund awarded just over A$2 million toward the TIA RNA Foundry at the University of Western Australia, within a combined A$6.85 million investment. This capacity joins Clayton, whose vaccine focus covers influenza, RSV and COVID-19. Together, these sites support the Therapeutic Innovation Australia national RNA network and shorten supply lines for local sponsors.

Rising consolidation among diagnostics and trial providers

Smaller diagnostics and clinical research providers are seeking scale, because laboratory costs and capital needs favor larger networks. Genetic Signatures and Microba Life Sciences announced preliminary merger talks on Aug. 26, 2026, although BiotechDispatch reported that no binding decision or terms were agreed. Nucleus Network bought Britain's Hammersmith Medicines Research in August 2025 and now cites more than 1,500 first-in-human studies, according to its release. Healius has also moved to a single national operating model, replacing four standalone businesses, according to Quartr's summary of its 2025 investor day. For buyers of in vitro diagnostics, these moves point to fewer vendors with broader test menus and national logistics.

Download Free Sample

Opportunity in disease-resistant and oil-trait crops

Licensed crop traits offer a commercial opening for agricultural biotechnology beyond the established cotton base. The Office of the Gene Technology Regulator issued license DIR 199 for the QCAV-4 banana, developed by Queensland University of Technology to resist Panama disease, and Food Standards Australia New Zealand cleared it for food on Feb. 16, 2024, according to ISAAA. The regulator's crop snapshot shows about 46% of the national canola crop was genetically modified in 2024, while almost all cotton is modified. Safflower with increased oleic acid has been released since 2018, and commercial safflower is mainly grown in New South Wales, Victoria and South Australia. Seed developers can therefore build on established grower familiarity when they introduce new traits.

Opportunity in precision fermentation and Queensland hubs

Fermentation and translational science give Queensland a route into industrial and vaccine work that does not depend on existing Melbourne plants. Cauldron plans its first industrial facility in Mackay at more than 1,000 metric tons a year, supported by Queensland's Industry Partnership Program, and already runs a 25,000-liter demonstration site in New South Wales, according to its September 2024 release. An A$280 million Translational Science Hub links the Queensland government, Sanofi, the University of Queensland and Griffith University under a December 2022 agreement. Queensland's government also reports more than 230 biomedical firms supporting regional demand for contract and trial services. As a result, Bioprocess and Material Optimization carries the fastest application growth at 9.68% a year across the forecast period.

Tax changes and uneven access slow younger companies

Research tax changes threaten mature pre-profit sponsors

The 2026–27 federal budget limits refundable research offsets to businesses under 10 years old from July 1, 2028, and removes supporting R&D from eligibility, according to Opportuna Legal. AusBiotech reported in June 2026 that 76% of 59 surveyed members expect significant or moderate effects. Companies aged six to 15 years are most exposed, since all of them expect an impact. As a result, some sponsors warn they could move critical trials overseas unless the design changes.

Rebate coverage leaves genomic access uneven

Medicare funding covers listed indications rather than every clinical need, so access depends on where a patient's condition sits on the schedule. Melbourne Genomics counted eight funded genomic tests as of October 2023, and the reproductive carrier rebate pays each parent A$300 to A$340. Laboratories and patients outside those items rely on hospital budgets, research studies or self-funding. Consequently, providers must plan volumes carefully until Genomics Australia and federal assessors extend coverage to further indications.

State limits narrow the planted area for modified crops

Regulatory approval does not guarantee planting, because states can still restrict cultivation for marketing reasons. In its December 2025 snapshot, the Office of the Gene Technology Regulator notes that the Australian Capital Territory, Tasmania and parts of South Australia restrict genetically modified crops, and that approved Indian mustard has not yet been planted. Seed developers therefore face smaller addressable areas than national licenses imply. Commercial cotton, by comparison, is grown in inland New South Wales and Victoria and in central and southern Queensland.

Thin capital and cost pressure test listed diagnostics

Smaller listed diagnostics companies have limited cash for commercial expansion, which slows launches and sales coverage. Genetic Signatures and Microba would hold about A$30 million in combined cash and term deposits at June 30, 2026, according to BiotechDispatch, and AusBiotech found 61% of surveyed members expect proposed capital gains changes to hurt them. Larger networks face pressure too, since Healius targets A$15 million to A$20 million in cost cuts. Partnerships and merger talks are therefore the visible response among smaller listed suppliers.

Victoria and New South Wales lead, Queensland gains

Victoria and New South Wales hold the plants and the clusters

Victoria and New South Wales held 53.9% of 2025 value and grow at 7.71% a year. BiotechDispatch reported in June 2022 that the two states host 73% of sector organizations in the AusBiotech snapshot. The Australian Bureau of Statistics counted about 15.82 million residents there at March 31, 2026. Tullamarine, Clayton and Macquarie Park supply most sovereign capacity, while Telix lists a North Melbourne manufacturing site opening as a 2026 milestone.

Queensland gains from biomedical investment and fermentation

Queensland held 19.0% of 2025 value and is the fastest-growing region at 8.51% a year. The Queensland government reports over 27,300 biomedical workers, about A$4.15 billion in annual gross value added and about A$533 million in exports. Nucleus Network operates an early-phase clinic in Brisbane, which draws sponsors into the state. Planned Mackay fermentation capacity and the ENTRI manufacturing facility, scheduled to open in 2026, give the state a broader industrial base than clinical services alone.

Download Free Sample

Western Australia builds on sterile manufacturing and RNA

Western Australia held 16.0% of 2025 value and grows at 8.21% a year. BioCina runs a 34,000-square-meter injectables site at Technology Park that has supplied medicines to 98 countries, according to the state's Future Health Research and Innovation Fund in December 2025. The TIA RNA Foundry at the University of Western Australia adds research-grade capacity. Population grew 2.1% in the year to March 2026, the fastest state rate, which supports clinical and pathology volumes.

South Australia, Tasmania and territories rely on specialist nodes

South Australia, Tasmania and Territories held 11.1% of 2025 value and grow at 7.81% a year. South Australia alone accounted for 5% of organizations and 135 entities in the 2022 AusBiotech snapshot reported by BiotechDispatch. The South Australian Genomics Centre, with its hub at SAHMRI in Adelaide, gives researchers spatial and single-cell services. Healius also won a Tasmanian Department of Health tender, according to Quartr's investor day summary, adding public volume in a smaller market.

Download Free Sample

Dated plants, rebates and approvals since 2024

Sequencing and cell platforms set service capability

• Cell-based biomanufacturing relies on dedicated plants such as CSL Seqirus at Tullamarine, which opened in late 2025 as a cell-based vaccine facility.
• Molecular assay platforms include the EasyScreen tests from Genetic Signatures, whose 3base chemistry is designed for high-volume hospital and pathology laboratories.
• Genomic sequencing spans Illumina, PacBio Revio and Oxford Nanopore PromethION instruments at university facilities, including the John Curtin School of Medical Research in Canberra.
• Computational biology supports these laboratories through services such as the bioinformatics platform at the South Australian Genomics Centre, which handles analysis, integration and visualization of sequence data.

Vaccines, radiopharma and pathology networks compete

Competition is organized around supply position rather than a single product category. CSL Limited holds the sovereign vaccine and antivenom role through its long-term federal agreement, while Telix Pharmaceuticals competes in radiopharmaceutical imaging and lists Illuccix as commercially available in Australia. Mesoblast and Imugene compete for trial capital with cell therapies, and Imugene runs its azer-cel Phase 1b study at five Australian sites. Clinuvel Pharmaceuticals, based in Melbourne, reached its Phase III vitiligo recruitment target in May 2025. Sonic Healthcare and Healius compete through national pathology networks, and Sonic also distributes Microba tests. Nucleus Network supplies early-phase trial capacity in Melbourne and Brisbane, and Genetic Signatures sells assays to hospital laboratories. Scale matters most in reimbursed services, whereas clinical data decides value among developers.

Companies profiled and their roles in this market

Reimbursement and tax design will decide the pace

Credence Research's view is that reimbursement design and research tax settings will shape this market more than laboratory capability does. Plants and sequencers are already funded, including Clayton, Tullamarine and Macquarie Park, yet younger sponsors depend on rules taking effect from July 1, 2028. Genomics services should keep gaining share because Medicare items and precision oncology funding are widening access. However, buyers should expect a thinner field of listed diagnostics suppliers if preliminary talks such as the Genetic Signatures and Microba discussions produce mergers. Sponsors with trial plans beyond 2028 should test offset eligibility now, because demand for local studies depends on those rules.

Public registers and releases underpin these estimates

The report uses 2025 as the base year and 2035 as the forecast year, with market values from the Credence Research model. Segment and regional splits are Credence Research estimates informed by public data. Sources used include Australian government releases, the Australian Bureau of Statistics, the Australian Institute of Health and Welfare, the Office of the Gene Technology Regulator, the U.S. Food and Drug Administration, company announcements and named trade publications. No primary interviews or surveys were conducted for this report.

Genomics services and bioprocessing outpace the base by 2035

The market is forecast to reach USD 17.14 billion by 2035 from USD 8.60 billion in 2026, a 7.96% CAGR across 2026–2035. Human health biologics will remain the base, while Genomics Services expands at 9.42% a year on wider Medicare coverage and precision oncology funding. Queensland should gain share as Mackay fermentation and hub projects mature. The main uncertainty is the 2028 tax change, because a narrower refundable offset could shift some trial spending overseas. Conversely, sovereign supply contracts running into the mid-2030s give manufacturers a stable volume floor through most of the forecast.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.